New England Journal of Medicine· 2018Q1

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, Steven G. DuBois et al.

2,759citations
Q1SCImago
2018year

Short summary

Larotrectinib achieved a 75% overall response rate (ORR) in adults and children with TRK fusion-positive cancers, with 71% of responses ongoing at 1 year.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Pulmonary and Respiratory Medicine

Pulmonary and Respiratory MedicineMedicine